Wells Fargo Upgrades Relay Therapeutics (RLAY) to Overweight
Tweet
Share
E-mailGet Alerts RLAY Hot Sheet
Price: $20.22 +0.75%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Join SI Premium – FREE
Wells Fargo analyst Eva Fortea Verdejo upgraded Relay Therapeutics (NASDAQ: RLAY) from Equal Weight to Overweight with a price target of $13.00.
For an analyst ratings summary and ratings history on Relay Therapeutics click here. For more ratings news on Relay Therapeutics click here.
Shares of Relay Therapeutics closed at $7.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Double Downgrades Mosaic (MOS) to Sell
- Wells Fargo Downgrades Bio-Techne Corp. (TECH) to Equal Weight
- Tencent Holdings (700:HK) (TCEHY) PT Lowered to HK$625 at Benchmark to Reflect Downward Earnings Revisions
Create E-mail Alert Related Categories
UpgradesRelated Entities
Wells Fargo, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
